Analyst Reco. The Chemours Company

Equities

CC

US1638511089

Market Closed - Nyse Other stock markets 21:00:02 26/04/2024 BST			5-day change	1st Jan Change
27.32 ^USD	+1.07%		+5.44%	-13.38%

04-26	Well, it isn't as bad as feared...
04-26	Chemours CFO Jonathan Lock steps down after financial revisions	RE

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BMO Capital Upgrades Chemours to Outperform From Underperform, Raises Price Target to $34 From $19	04-09	MT
UBS Adjusts Chemours Price Target to $28 From $21, Maintains Neutral Rating	04-02	MT
UBS Downgrades Chemours to Neutral From Buy, Cuts Price Target to $21 From $37	03-05	MT
BMO Capital Downgrades Chemours to Underperform From Outperform, Adjusts Price Target to $19 From $45	03-01	MT
RBC Upgrades Chemours to Outperform From Sector Perform, Lifts Price Target to $40 From $28 on Titanium Technologies Recovery, Thermal & Specialized Solutions Strength	12-01	MT
Goldman Sachs Adjusts Chemours' Price Target to $30 From $35, Maintains Neutral Rating	31/10/23	MT
BMO Capital Adjusts Chemours' PT to $39 From $45, Keeps Outperform Rating	30/10/23	MT
Morgan Stanley Cuts Price Target on Chemours to $28 From $33, Maintains Equal-Weight Rating	30/10/23	MT
Barclays Cuts Price Target on Chemours to $28 From $31, Maintains Equal-Weight Rating	30/10/23	MT
RBC Cuts Price Target on Chemours to $28 From $30, Keeps Sector Perform Rating	30/10/23	MT
UBS Cuts Chemours Price Target to $37 From $41, Maintains Buy Rating	27/10/23	MT
RBC Cuts Price Target on Chemours to $30 From $40, Keeps Sector Perform Rating	23/10/23	MT
BofA Securities Adjusts Price Target on Chemours to $32 From $39, Maintains Neutral Rating	18/10/23	MT
UBS Cuts Chemours Price Target to $41 From $47, Maintains Buy Rating	09/10/23	MT
Barclays Adjusts Price Target on Chemours to $31 From $40, Keeps Equalweight Rating	04/10/23	MT
BMO Capital Adjusts Price Target on Chemours to $53 From $64, Maintains Outperform Rating	02/08/23	MT
RBC Boosts Price Target on Chemours to $40 From $37, Maintains Sector Perform Rating	31/07/23	MT
UBS Adjusts Chemours Price Target to $47 From $43, Maintains Buy Rating	28/07/23	MT
Barclays Adjusts Price Target on Chemours Company to $40 From $38, Maintains Equalweight Rating	11/07/23	MT
BofA Securities Downgrades Chemours to Neutral From Buy, Lowers Price Target to $37 From $41	22/06/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. The Chemours Company

Equities

CC

US1638511089

Analyst Reco.

Filters